Paclitaxel triggers suicidal erythrocyte death or eryptosis, characterized by exposure of phosphatidylserine at the erythrocyte surface and cell shrinkage. Eryptosis of infected erythrocytes may delay development of parasitemia and thus favourably influence the course of malaria. The present study explored whether paclitaxel influences in vitro parasite growth and eryptosis of Plasmodium falciparum infected human erythrocytes and in vivo parasitemia and survival of Plasmodium berghei infected mice. Phosphatidylserine exposing erythrocytes were identified utilizing annexin V binding and erythrocyte volume was estimated from forward scatter in FACS analysis. In vitro infection of human erythrocytes with P. falciparum increased annexin binding and decreased forward scatter, effects augmented in the presence of paclitaxel (≥ 0.01 µM). Paclitaxel (≥ 0.01 µM) significantly decreased intraerythrocytic DNA/RNA content and in vitro parasitemia. In Plasmodium berghei infected mice parasitemia was significantly decreased (from 55.8% to 28.6% of circulating erythrocytes 20 days after infection) and mouse survival significantly enhanced (from 0% to 69.23% 25 days after infection) by administration of 8.5 mg/ kg.b.w. of paclitaxel intraperitoneally from the eighth day of infection. In conclusion, paclitaxel decreases parasitemia and enhances survival of P. berghei infected mice, an effect, which may be due to stimulation of eryptosis and/or a direct toxic effect on the parasite.
Introduction
Paclitaxel and the related drug docetaxel are anticancer drugs employed for the treatment of malignancies [1] [2] [3] [4] . Paclitaxel is also used for the prevention of restenosis [5] . The substances may lead to cellular growth arrest [6] . They are considered to be primarily effective through interference with the cytoskeleton [7, 8] and p53 signaling [9] as well as stimulation of caspases [10, 11] . Paclitaxel similarly elicits eryptosis [12] , the suicidal death of erythrocytes. Eryptosis is characterized by cell shrinkage and cell membrane scrambling leading to exposure of phosphatidylserine at 192 the cell surface [13] [14] [15] [16] [17] . Cell membrane scrambling is triggered by increased cytosolic Ca 2+ activity [13, 15, 16, 18] and ceramide [19] . Ca 2+ enters into erythrocytes through Ca 2+ permeable cation channels which are activated by osmotic shock, oxidative stress and energy depletion [18, [20] [21] [22] . Ca 2+ further activates Ca 2+ sensitive K + channels [23, 24] leading to exit of KCl and osmotically obliged water and thus to cell shrinkage [25] . Ca 2+ could similarly stimulate apoptosis of nucleated cells [26] . Paclitaxel triggers eryptosis by increase of cytosolic Ca 2+ activity, ceramide formation and activation of calpain [12] .
Macrophages are equipped with receptors specific for phosphatidylserine [27, 28] , and phagocytose phosphatidylserine exposing erythrocytes [29, 30] , which are thus rapidly eliminated from circulating blood.
Accelerated eryptosis underlies several anemic conditions [31] , such as sickle-cell anemia [32] , betathalassemia [17] , glucose-6-phosphate dehydrogenase (G6PD)-deficiency [17] , phosphate depletion [33] , iron deficiency [34] , Hemolytic Uremic Syndrome [35] , sepsis [36] , malaria [37] and Wilson disease [38] . Moreover, enhanced eryptosis is stimulated by hemolysin Kanagawa [39] , listeriolysin [40] , IgA antibodies [41] , azathioprine [42] , selenium componnds [43] , platelet activating factor [44] , lipopetides [45] , cadmium ions [46] , ciglitazone [47] , curcumin [48] , amyloid peptides [49] , valinomycin [50] , retinoic acid [51] , amiodarone [52] , anandamide [53] , copper ions [38] and paclitaxel [12] .
During malaria, stimulation of eryptosis may result in the clearance of infected erythrocytes prior to the development of trophozoites with the ability to intoxicate macrophages [54] . Accelerated eryptosis has thus been considered a protective mechanism in malaria [37] . Accordingly, sickle-cell trait, beta-thalassemia-trait, homozygous Hb-C and G6PD-deficiency lead to premature senescence and/or eryptosis upon infection with Plasmodium thus leading to accelerated clearance of ring stage-infected erythrocytes [17, [55] [56] [57] [58] [59] .
The present study explored whether paclitaxel triggers phosphatidylserine exposure of Plasmodium falciparum (P. falciparum) infected erythrocytes and influences parasitemia and survival of Plasmodium berghei (P. berghei) infected mice.
Materials and Methods

Animals, cells and solutions
Animal experiments were performed according to German animal protection law and approved by the local authorities (registration number PY 2/06). Healthy SV129/J wild type mice (aged 4 months, both male and female) were used for the experiments. Mouse erythrocytes were drawn from animals by retroorbital venopuncture or by incision of the tail vein. Human erythrocytes were drawn from healthy volunteers.
Experiments were performed at 37°C in Ringer solution containing (in mM) 125 NaCl, 5 KCl, 1 MgSO 4 , 32 N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES)/ NaOH (pH 7.4), 5 glucose, 1 CaCl 2. Paclitaxel was added to the NaCl Ringer at final concentrations varying from 0.001 µM to 1 µM (Sigma, Taufkirchen, Germany). For in vitro paclitaxel treatment, the final haematocrit was adjusted to 0.3%.
Determination of phosphatidylserine exposure
FACS analysis was performed as described [18] . After incubation in the presence or absence of paclitaxel, suspensions of noninfected erythrocytes were stained with annexin V-FLUOS (Roche, Mannheim,Germany), suspensions of Plasmodium falciparum infected erythrocytes were stained with annexin V-APC (BD Biosciences Pharmingen, Heidelberg, Germany) and/or with the DNA/RNA specific dye Syto16 (Molecular Probes, Göttingen, Germany) to identify phosphatidylserine exposing and infected erythrocytes, respectively. 
In vitro cultivation of Plasmodium falciparum
For infection of human erythrocytes the human pathogen Plasmodium falciparum strain BinH [60] was grown in vitro [61] in human erythrocytes. Parasites were cultured as described earlier [62, 63] at a haematocrit of 2% and a parasitemia of 2-10% in RPMI 1640 medium supplemented with Albumax II (0.5%; Gibco, Karlsruhe, Germany) in an atmosphere of 90% N 2 , 5% CO 2 , 5% O 2 .
In vivo proliferation of Plasmodium berghei P. falciparum is not pathogenic in mice and thus, the in vivo experiments in mice have been performed with P. berghei, which is not pathogenic to human erythrocytes and cannot be used for in vitro experiments. The mice were infected with Plasmodium berghei ANKA-parasitized mouse erythrocytes (1x10 6 ) which were injected intraperitoneally [64] into wildtype mice with free access to water. The treated group additionally received paclitaxel (8.54 mg/kg b.w.) intraperitoneally from the eighth day of infection. Blood was collected from the mice 8 days after infection by incision of the tail. Parasitemia was determined by DNA/RNA specific fluorescence dye Syto16 staining detected by FL-1 in FACS analysis. The erythrocytes were stained with 1µM Syto 16 in PBS and incubated for 20 min Koka/Bobbala/Lang/Boini/Huber/Lang Cell Physiol Biochem 2009; 23:191-198 at 37°C. The percentage of stained/infected erythocytes was determined within the total popuplaton of erythrocytes.
In vitro growth assays of P. falciparum infected human erythrocytes
The Plasmodium falciparum BinH strain was cultured and synchronized to the ring stage by sorbitol treatment as described previously [65] . For the in vitro growth assay, synchronized parasitized erythrocytes were aliquoted in 96-well plates (200 µl aliquots, 1% haematocrit, 0.5 -2% parasitemia) and grown for 48 h in the presence or absence of paclitaxel (0.001 µM -1 µM) and/or docetaxel (0.001µM -1 µM). The parasitemia was assessed at time 0 and after 48 h of culture by flow cytometry. Parasitemia was defined by the percentage of erythrocytes stained with the DNA/RNA specific fluorescence dye Syto16.
To estimate DNA/RNA amplification, the culture was ring stage-synchronized, and re-synchronized after 6 h of culture (to narrow the developmental parasite stage), aliquoted (200 µl aliquots, 2% haematocrit and 10% parasitemia) and cultured for further 16 h in the presence or absence of paclitaxel (0.001 µM -1 µM). Thereafter, the DNA/RNA amount of the parasitized erythrocytes was determined by Syto16 fluorescence as a measure of intraerythrocytic parasite copies.
Statistics
Data are expressed as arithmetic means ± SEM and statistical analysis was made by paired or unpaired t-test or ANOVA using Tukey's test as post hoc test, where appropriate. p<0.05 was considered as statistically significant.
Results
Annexin V binding has been utilized to identify phosphatidylserine exposing erythrocytes in FACS analysis. In freshly drawn human blood the percentage of annexin-binding erythrocytes was low (0.91 ± 0.07 %, n = 6). Incubation of noninfected human erythrocytes in Ringer solution increased the percentage of annexin binding cells within 24 hours to 2.98 ± 0.29 % (n = 6). Infection with P. falciparum for 24h significantly enhanced the percentage of annexin binding human erythrocytes (Fig. 1) . The presence of paclitaxel significantly enhanced the annexin binding of both infected erythrocytes and the co-incubated noninfected erythrocytes (Fig. 1) . The effect reached statistical significance at 0.001 µM and 0.1µM paclitaxel in the infected and noninfected erythrocytes, respectively. Thus, paclitaxel potentiated the scrambling effect of infection on phosphatidylserine exposure.
Incubation of non-infected erythrocytes with lower concentrations of paclitaxel for extended periods tended to increase annexin binding, an effect, however, not reaching statistical significance. The annexin binding of noninfected erythrocytes after 48h incubation was 3.90 ± 0.44, 4.02 ± 0.23, 4.21 ± 0.38 and 4.6 ± 0.21 (n = 8 each) at 0, 0.001, 0.01, 0.05 µM of paclitaxel respectively.
Intraerythrocytic DNA amplification in erythrocytes was slightly, but significantly decreased by paclitaxel (≥ 0.01 µM) ( Fig. 2A) . In vitro growth of Plasmodium falciparum in human erythrocytes was similarly decreased at paclitaxel concentrations (≥ 0.01 µM) (Fig.  2B) . The in vitro growth of Plasmodium falciparum in human erythrocytes in the presence of docetaxel or the combination of both docetaxel and paclitaxel was similar to that of Paclitaxel (Fig. 2 C,D) .
The forward scatter, which reflects the cell volume was at early stages of infection similar, at later stages significantly larger in infected than in noninfected erythrocytes. Paclitaxel slightly decreased the forward scatter, an effect reaching statistical significance at 1µM concentration both in the early and late stage P. falciparum infected erythrocytes (Fig. 3 A, B) .
To determine the influence of paclitaxel treatment on the course of malaria in vivo, mice were infected with Plasmodium berghei. Parasitemia was less than 10% 8 days after infection but gradually increased the next 10 days (Fig. 4) . Without paclitaxel treatment, the percentage of parasitized erythrocytes increased up to 55.8% within 20 days. Following treatment with Fig. 4A, B) . Most importantly, paclitaxel treatment increased the survival of Plasmodium berghei infected mice. Whereas all nontreated animals died within 30 days after the infection, 69% of the paclitaxel treated animals survived the infection for more than 30 days (Fig. 4C) .
Discussion
The present study reveals a significant favorable effect of paclitaxel on the course of malaria. Following infection with Plasmodium berghei the increase of parasitemia was significantly less rapid in paclitaxel treated mice than in untreated mice. Moreover, paclitaxel significantly increased the survival of Plasmodium berghei infected mice. Similar to what has been shown earlier [64] , untreated mice all die from infection with Plasmodium berghei. In contrast, some 2/3 of the paclitaxel treated mice survived the first 30 days following infection. Most of those mice recovered from the infection. Thus, paclitaxel treatment indeed favourably modifies the course of malaria.
The effect of paclitaxel could be related to the ability of the drug to induce eryptosis [12] . Paclitaxel has previously been shown to induce eryptosis by increasing cytosolic Ca 2+ activity, stimulating ceramide formation and activating calpain [12] . Paclitaxel is effective in both, infected and noninfected cells. The combination of infection and paclitaxel exposure leads to excessive scrambling of the cell membrane. The subsequent phosphatidylserine exposure at the cell surface is an "eat me" signal for macrophages [29, 30] . Paclitaxel further decreases cell volume, which is presumably due to increase of cytosolic Ca hyperpolarization of the erythrocyte membrane potential and Cl -exit [66] . The exit of KCl is followed by osmotically obliged water and thus leads to cell shrinkage [67] . Phosphatidylserine exposure and cell shrinkage are the hallmarks of eryptosis [68] .
Infection of erythrocytes with Plasmodium falciparum similarly triggers eryptosis [69, 70] . Plasmodia impose oxidative stress to the host erythrocyte leading to activation of the Ca 2+ permeable cation channels [65] with subsequent cell membrane scrambling and phosphatidylserine exposure at the erythrocyte surface [71] .
The favourable effect of paclitaxel on the course of malaria may partially result from a direct toxic action on the pathogen, as paclitaxel slighty, but significantly decreased the intraerythrocytic DNA/RNA content.
Alternatively, the favourable effect may result from the scrambling effect of paclitaxel, which decreases the life span of infected erythrocytes in circulating blood. Iron deficiency [69] and treatment with lead [70] have similarly been shown to accelerate eryptosis of infected erythrocytes and are thus similarly protective against a severe course of malaria.
In conclusion, paclitaxel augments eryptosis of infected erythrocytes, thus fostering the clearance of infected erythrocytes from circulating blood. Accordingly, paclitaxel favourably influences the course of malaria in mice. Future studies have to explore, whether paclitaxel is similarly effective in the treatment of malaria in man.
